Pneumococcal Vaccine Snags Breakthrough Therapy Designation

Pneumococcal Vaccine Snags Breakthrough Therapy Designation

Source: 
BioSpace
snippet: 

A mid-stage clinical study of an experimental vaccine for Streptococcus pneumoniae is showing promise. Phase II data shows the vaccine candidate developed by Affinivax and Astellas Pharma is well tolerated and generated an antibody response against the deadly bacterial infection.